Exact公司开发出大肠癌的粪便DNA筛查技术

 
 
在一项前瞻性、多中心临床研究中发现，一种使用粪便中DNA的非创伤性大肠癌筛查方法，其敏感性达到了88%。

在2006年5月美国洛杉矶(CA, USA)举行的消化疾病周(DDW)年度会议上报道了这项研究结果，DDW是一项国际胃肠病学专家的盛会。采用盲法研究主要是为了验证该技术的效果，以提高粪便样本中大肠癌的检出率。

使用经过简化的基因标志物检测盘、DNA稳定缓冲液、DNA增强捕获技术，Exact科学公司(Marlborough, MA., USA)的第2代粪便DNA技术，在这项采用盲法设计的临床研究中，结肠癌的检测敏感性达到了88%。该研究还证实了第1代粪便DNA检测技术如果使用DNA缓冲液之后，敏感性可以达到73%。
 
Colon Cancer Screening Based on Stool DNA
 
A non-invasive screening method for colon cancer using stool DNA demonstrated 88% sensitivity in a prospective, multi-center study.

The results of the study were presented at the annual Digestive Disease Week (DDW) conference in May 2006 in Los Angeles (CA, USA) , an international meeting of gastroenterology professionals. The blinded study was designed to test the efficacy of technologic advances to enhance colorectal-cancer detection in stool samples.

Using a simplified panel of genetic markers, a buffer for DNA stabilization, and an enhanced DNA capture technology, Exact Sciences’ (Marlborough, MA., USA) second generation stool DNA technology demonstrated 88% sensitivity for colorectal cancer in this blinded study. The study also confirmed that the first generation stool DNA technology demonstrated a sensitivity of 73% with use of the DNA stabilization buffer.